Trial Outcomes & Findings for Evaluate the Utility of Serum Hepcidin Levels to Predict Response to Oral or IV Iron (NCT NCT01950247)
NCT ID: NCT01950247
Last Updated: 2025-05-22
Results Overview
The MAF scale has 16 items that measure the Global Fatigue Index (GFI), a composite score of Items 1 through 15. Items 1 through 14 were measured on a scale of 1 to 10, with 1 = not at all and 10 = a great deal. Items 15 and 16 had categorical responses: degree of agreement from 0 to 4, with 0=no days and 4=every day. Then, a Global Fatigue Index (GFI) is calculated by summing specific items and averaging others. The final GFI score ranges from 1 (no fatigue) to 50 (severe fatigue). The resulting score is given as the mean value.
COMPLETED
PHASE4
1025 participants
Baseline to Day 30
2025-05-22
Participant Flow
Participant milestones
| Measure |
IV Iron Standard of Care (SOC)
At a dose and administration regimen as determined by the study site investigator
Standard of Care (SOC)
|
Injectafer
2 doses at 15 mg/kg for a maximum single dose of 750 mg given 7 days apart for a total of up to 1500 mg.
Injectafer: 2 doses at 15 mg/kg for a maximum single dose of 750 mg given 7 days apart for a total of up to 1500 mg.
|
|---|---|---|
|
Overall Study
STARTED
|
512
|
513
|
|
Overall Study
COMPLETED
|
455
|
467
|
|
Overall Study
NOT COMPLETED
|
57
|
46
|
Reasons for withdrawal
| Measure |
IV Iron Standard of Care (SOC)
At a dose and administration regimen as determined by the study site investigator
Standard of Care (SOC)
|
Injectafer
2 doses at 15 mg/kg for a maximum single dose of 750 mg given 7 days apart for a total of up to 1500 mg.
Injectafer: 2 doses at 15 mg/kg for a maximum single dose of 750 mg given 7 days apart for a total of up to 1500 mg.
|
|---|---|---|
|
Overall Study
Withdrawal by Subject
|
28
|
13
|
|
Overall Study
Lost to Follow-up
|
18
|
16
|
|
Overall Study
Physician Decision
|
3
|
4
|
|
Overall Study
Adverse Event
|
3
|
2
|
|
Overall Study
Death
|
1
|
1
|
|
Overall Study
Not Defined
|
4
|
10
|
Baseline Characteristics
Evaluate the Utility of Serum Hepcidin Levels to Predict Response to Oral or IV Iron
Baseline characteristics by cohort
| Measure |
Injectafer
n=513 Participants
2 doses at 15 mg/kg for a maximum single dose of 750 mg given 7 days apart for a total of up to 1500 mg.
Injectafer: 2 doses at 15 mg/kg for a maximum single dose of 750 mg given 7 days apart for a total of up to 1500 mg.
|
IV Iron Standard of Care (SOC)
n=512 Participants
At a dose and administration regimen as determined by the study site investigator
SOC
|
Total
n=1025 Participants
Total of all reporting groups
|
|---|---|---|---|
|
Age, Continuous
|
57.2 years
STANDARD_DEVIATION 16.58 • n=99 Participants
|
55.7 years
STANDARD_DEVIATION 16.68 • n=107 Participants
|
56.5 years
STANDARD_DEVIATION 16.64 • n=206 Participants
|
|
Sex: Female, Male
Female
|
421 Participants
n=99 Participants
|
409 Participants
n=107 Participants
|
830 Participants
n=206 Participants
|
|
Sex: Female, Male
Male
|
92 Participants
n=99 Participants
|
103 Participants
n=107 Participants
|
195 Participants
n=206 Participants
|
|
Region of Enrollment
United States
|
513 Participants
n=99 Participants
|
512 Participants
n=107 Participants
|
1025 Participants
n=206 Participants
|
PRIMARY outcome
Timeframe: Baseline to Day 30Population: Change from baseline to Day 30
The MAF scale has 16 items that measure the Global Fatigue Index (GFI), a composite score of Items 1 through 15. Items 1 through 14 were measured on a scale of 1 to 10, with 1 = not at all and 10 = a great deal. Items 15 and 16 had categorical responses: degree of agreement from 0 to 4, with 0=no days and 4=every day. Then, a Global Fatigue Index (GFI) is calculated by summing specific items and averaging others. The final GFI score ranges from 1 (no fatigue) to 50 (severe fatigue). The resulting score is given as the mean value.
Outcome measures
| Measure |
Injectafer
n=264 Participants
2 doses at 15 mg/kg for a maximum single dose of 750 mg given 7 days apart for a total of up to 1500 mg.
Injectafer: 2 doses at 15 mg/kg for a maximum single dose of 750 mg given 7 days apart for a total of up to 1500 mg.
|
IV Iron Standard of Care (SOC)
n=269 Participants
At a dose and administration regimen as determined by the study site investigator
SOC
|
|---|---|---|
|
Multidimensional Assessment of Fatigue (MAF) Scores
|
-8.8 units on a scale
Standard Deviation 11.38
|
-8.1 units on a scale
Standard Deviation 11.28
|
PRIMARY outcome
Timeframe: Baseline and Day 30Population: Change from baseline to Day 30
The WPAI consisted of six questions: 1 = currently employed; 2 = hours missed due to health problems; 3 = hours missed other reasons; 4 = hours actually worked; 5 = degree health affected productivity while working using a scale of 0 to 10, with 0 = PROBLEM had no effect on my work and 10 = PROBLEM completely prevented me from working; 6 = degree health affected productivity in regular unpaid activities using a scale of 0 to 10, with 0 = PROBLEM had no effect on my daily activities and 10 = PROBLEM completely prevented me from doing my daily activities. It yields 4 sub-scores: work time missed (absenteeism), impairment while working (presenteeism or reduced on-the-job effectiveness), overall work impairment (work productivity loss or absenteeism plus presenteeism) and activity impairment (daily activity impairment). These sub-scores are transformed to impairment percentages (range from 0 to 100), with higher numbers indicating greater impairment and less productivity.
Outcome measures
| Measure |
Injectafer
n=513 Participants
2 doses at 15 mg/kg for a maximum single dose of 750 mg given 7 days apart for a total of up to 1500 mg.
Injectafer: 2 doses at 15 mg/kg for a maximum single dose of 750 mg given 7 days apart for a total of up to 1500 mg.
|
IV Iron Standard of Care (SOC)
n=512 Participants
At a dose and administration regimen as determined by the study site investigator
SOC
|
|---|---|---|
|
Work Productivity and Activity Impairment Questionnaire (WPAI) Scores
Percent activity impairment due to problem
|
-15.2 units on a scale
Standard Deviation 29.85
|
-11.5 units on a scale
Standard Deviation 29.43
|
|
Work Productivity and Activity Impairment Questionnaire (WPAI) Scores
Percent impairment while working due to problem
|
-13.2 units on a scale
Standard Deviation 28.75
|
-8.5 units on a scale
Standard Deviation 24.44
|
|
Work Productivity and Activity Impairment Questionnaire (WPAI) Scores
Percent overall work impairment due to problem
|
-13.4 units on a scale
Standard Deviation 31.66
|
-8.5 units on a scale
Standard Deviation 25.89
|
|
Work Productivity and Activity Impairment Questionnaire (WPAI) Scores
Percent work time missed due to problem
|
-3.2 units on a scale
Standard Deviation 23.76
|
-2.5 units on a scale
Standard Deviation 17.23
|
PRIMARY outcome
Timeframe: Baseline and Day 30Population: Change from baseline to Day 30
Participants rated 14 items with 4 domains. Scores for item 1 to 3, 9 to 11 and 14 ranged from 1=extremely dissatisfied to 7=extremely satisfied. Items 5 to 8, 12, 13 ranged from 1=extremely dissatisfied to 5=not at all dissatisfied. Item 4 was scored as: 0=No, 1=Yes. Effectiveness measured as (\[{sum of item 1 to 3} - 3\]/18)\*100; if 1 question (Q) was missing: (\[{sum of item 1 to 3} -2\]/12)\*100. Side-effect measured as if item 4=No, score=100; if not then (\[{sum of item 5 to 8} -4\]/16)\*100; if 1 Q was missing: (\[{sum of item 5 to 8} -3\]/12)\*100. Convenience measured as (\[{sum of item 9 to 11} -3\]/18)\*100; if 1 Q was missing: (\[{sum of item 9 to 11} - 2\]/12)\*100. Global satisfaction as (\[{sum of item 12 to 14} -3\]/14)\*100; if item 12 or 13 was missing: (\[{sum of item 12 to 14} -2\]/10)\*100; if item 14 was missing: (\[{sum of item 12 and 13} -2\]/8)\*100. All domains had scale of 0 (no satisfaction) to 100 (best level of satisfaction), higher score equals greater satisfaction
Outcome measures
| Measure |
Injectafer
n=513 Participants
2 doses at 15 mg/kg for a maximum single dose of 750 mg given 7 days apart for a total of up to 1500 mg.
Injectafer: 2 doses at 15 mg/kg for a maximum single dose of 750 mg given 7 days apart for a total of up to 1500 mg.
|
IV Iron Standard of Care (SOC)
n=512 Participants
At a dose and administration regimen as determined by the study site investigator
SOC
|
|---|---|---|
|
Treatment Satisfaction Questionnaire for Medication Version 1.4 Scores
Overall Satisfaction
|
72.6 units on a scale
Standard Deviation 25.03
|
72.7 units on a scale
Standard Deviation 21.07
|
|
Treatment Satisfaction Questionnaire for Medication Version 1.4 Scores
Effectiveness
|
69.3 units on a scale
Standard Deviation 22.38
|
66.5 units on a scale
Standard Deviation 21.75
|
|
Treatment Satisfaction Questionnaire for Medication Version 1.4 Scores
Side Effects
|
63.5 units on a scale
Standard Deviation 27.21
|
69.2 units on a scale
Standard Deviation 21.00
|
|
Treatment Satisfaction Questionnaire for Medication Version 1.4 Scores
Convenience
|
78.9 units on a scale
Standard Deviation 17.31
|
72.8 units on a scale
Standard Deviation 20.00
|
PRIMARY outcome
Timeframe: Baseline and Day 30Population: Change from Baseline to Day 30
The SF-12 is a multipurpose short form to measure health status. There are 10 domains: Physical Composite Index (score range from 0-100); Physical Functioning Index (score range from 0-100); Role Limitation Physical Index (score range 0-100); Pain Index Score (score range from 0-100); General Health Index (score range from 0-100); Mental Health Composite Index (score range from 1-100); Vitality Index (score range from 0-100); Social Functioning Index (score rang 0-100); Role Limitation Emotional Index (score range 0-100); and SF-12 Mental Health Index (score range from 0-100), the higher the score means a better outcome. The overall scale and sub-scales were calculated with the standard SF-12 formulas.
Outcome measures
| Measure |
Injectafer
n=513 Participants
2 doses at 15 mg/kg for a maximum single dose of 750 mg given 7 days apart for a total of up to 1500 mg.
Injectafer: 2 doses at 15 mg/kg for a maximum single dose of 750 mg given 7 days apart for a total of up to 1500 mg.
|
IV Iron Standard of Care (SOC)
n=512 Participants
At a dose and administration regimen as determined by the study site investigator
SOC
|
|---|---|---|
|
Short Form Health Survey, 12-Item (SF-12) v2 Quality of Life Scores.
Role Limitation Physical
|
4.0 units on a scale
Standard Deviation 9.53
|
3.9 units on a scale
Standard Deviation 9.25
|
|
Short Form Health Survey, 12-Item (SF-12) v2 Quality of Life Scores.
Vitality
|
7.7 units on a scale
Standard Deviation 11.36
|
7.0 units on a scale
Standard Deviation 11.53
|
|
Short Form Health Survey, 12-Item (SF-12) v2 Quality of Life Scores.
Pain
|
1.6 units on a scale
Standard Deviation 10.03
|
2.5 units on a scale
Standard Deviation 10.52
|
|
Short Form Health Survey, 12-Item (SF-12) v2 Quality of Life Scores.
Overall Physical Health Score
|
3.3 units on a scale
Standard Deviation 7.94
|
3.1 units on a scale
Standard Deviation 8.33
|
|
Short Form Health Survey, 12-Item (SF-12) v2 Quality of Life Scores.
Overall Mental Health Score
|
3.7 units on a scale
Standard Deviation 10.31
|
3.7 units on a scale
Standard Deviation 10.39
|
|
Short Form Health Survey, 12-Item (SF-12) v2 Quality of Life Scores.
Physical Functioning
|
3.6 units on a scale
Standard Deviation 10.42
|
3.4 units on a scale
Standard Deviation 10.45
|
|
Short Form Health Survey, 12-Item (SF-12) v2 Quality of Life Scores.
General Health
|
3.2 units on a scale
Standard Deviation 9.86
|
2.5 units on a scale
Standard Deviation 9.84
|
|
Short Form Health Survey, 12-Item (SF-12) v2 Quality of Life Scores.
Social Functioning
|
3.6 units on a scale
Standard Deviation 12.19
|
3.0 units on a scale
Standard Deviation 11.47
|
|
Short Form Health Survey, 12-Item (SF-12) v2 Quality of Life Scores.
Role Limitation Emotion
|
2.7 units on a scale
Standard Deviation 12.69
|
2.8 units on a scale
Standard Deviation 12.62
|
|
Short Form Health Survey, 12-Item (SF-12) v2 Quality of Life Scores.
Mental Health
|
2.9 units on a scale
Standard Deviation 10.10
|
3.3 units on a scale
Standard Deviation 9.62
|
Adverse Events
Injectafer
IV Iron Standard of Care (SOC)
Serious adverse events
| Measure |
Injectafer
n=513 participants at risk
2 doses at 15 mg/kg for a maximum single dose of 750 mg given 7 days apart for a total of up to 1500 mg.
Injectafer: 2 doses at 15 mg/kg for a maximum single dose of 750 mg given 7 days apart for a total of up to 1500 mg.
|
IV Iron Standard of Care (SOC)
n=512 participants at risk
At a dose and administration regimen as determined by the study site investigator
SOC
|
|---|---|---|
|
Cardiac disorders
Cardiac disorders
|
0.78%
4/513 • Number of events 506 • Day 1 to Day 30
Adverse events were collected by systematic assessment
|
0.20%
1/512 • Number of events 486 • Day 1 to Day 30
Adverse events were collected by systematic assessment
|
Other adverse events
| Measure |
Injectafer
n=513 participants at risk
2 doses at 15 mg/kg for a maximum single dose of 750 mg given 7 days apart for a total of up to 1500 mg.
Injectafer: 2 doses at 15 mg/kg for a maximum single dose of 750 mg given 7 days apart for a total of up to 1500 mg.
|
IV Iron Standard of Care (SOC)
n=512 participants at risk
At a dose and administration regimen as determined by the study site investigator
SOC
|
|---|---|---|
|
Gastrointestinal disorders
Nausea
|
5.5%
28/513 • Number of events 506 • Day 1 to Day 30
Adverse events were collected by systematic assessment
|
4.1%
21/512 • Number of events 486 • Day 1 to Day 30
Adverse events were collected by systematic assessment
|
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place